NCT05567835 2026-02-23
TOGAR
Baylor College of Medicine
Phase 2 Terminated
Clinical Trials
130 trialsNCT04095689 2026-01-23
INTEGRAL
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT05481645 2026-01-09
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT04854499 2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2 Terminated
NCT04396535 2025-11-17
Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer
Mayo Clinic
Phase 2 Terminated
NCT06046482 2025-10-22
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05461794 2025-06-13
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
BeiGene
Phase 2 Terminated
NCT03442556 2025-06-12
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
University of Washington
Phase 2 Terminated
NCT04827576 2025-05-08
ELEVATELung&UC
Gilead Sciences
Phase 2 Terminated
NCT03764540 2025-04-13
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Terminated
NCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT04937738 2024-11-06
PECORINO
Ukrainian Society of Clinical Oncology
Phase 2 Terminated
NCT05148195 2024-03-13
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT03228186 2023-10-23
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT03737123 2023-09-13
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03329378 2023-08-22
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT00786682 2023-08-14
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00551759 2023-07-03
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT02516670 2023-06-07
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT02124902 2022-11-07
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Washington University School of Medicine
Phase 2 Terminated
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT03041181 2022-07-11
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Hoosier Cancer Research Network
Phase 2 Terminated
NCT01741155 2021-10-13
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT01773785 2021-10-13
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT02387216 2021-10-12
SHERLOC
Elevation Oncology
Phase 2 Terminated
NCT03894007 2021-09-23
PREDIXIIHER2
Karolinska University Hospital
Phase 2 Terminated
NCT02985021 2021-08-05
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
Seattle Institute for Biomedical and Clinical Research
Phase 2 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT02685267 2021-04-09
Doce/Enza
Prostate Cancer Clinical Trials Consortium
Phase 2 Terminated
NCT00066677 2021-03-05
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT03256721 2021-02-08
Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
Fuzhou General Hospital
Phase 2 Terminated
NCT00285415 2021-02-05
A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation
Carilion Clinic
Phase 2 Terminated
NCT01194960 2020-10-19
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
Oxford BioMedica
Phase 2 Terminated
NCT03093272 2020-04-09
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT00582582 2019-12-13
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT01253642 2019-10-02
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01646125 2019-07-24
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Novartis
Phase 2 Terminated
NCT01967875 2019-05-30
A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
China Medical University, China
Phase 2 Terminated
NCT02718482 2019-05-13
OsteoREC2015
Italian Sarcoma Group
Phase 2 Terminated
NCT00979641 2019-03-28
AINO
Tampere University Hospital
Phase 2 Terminated
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT02560051 2018-11-28
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT02494713 2018-11-27
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00315211 2018-08-20
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
Aultman Health Foundation
Phase 2 Terminated
NCT01608464 2018-08-10
Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer
King Faisal Specialist Hospital & Research Center
Phase 2 Terminated